Polar Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Polar Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-471,362	Closed	-$12.6M	–	316
2019 Q3	$12.6M	Buy	+471,362	New	+$13.2M	0.11%	181
2018 Q1	–	Sell	-588,200	Closed	-$28.6M	–	282
2017 Q4	$28.6M	Hold	588,200	–	–	0.3%	107
2017 Q3	$31.8M	Buy	588,200 +250,700	+74%	+$14.7M	0.36%	92
2017 Q2	$19M	Buy	+337,500	New	+$13.5M	0.26%	125
2016 Q1	–	Sell	-520,000	Closed	-$26.8M	–	287
2015 Q4	$26.8M	Sell	520,000 -12,987	-2%	-$630K	0.48%	61
2015 Q3	$22.7M	Buy	532,987 +15,361	+3%	+$741K	0.46%	72
2015 Q2	$23.6M	Sell	517,626 -50,021	-9%	-$2.01M	0.45%	73
2015 Q1	$21.5M	Sell	567,647 -92,282	-14%	-$3.17M	0.41%	78
2014 Q4	$18.7M	Buy	659,929 +159,929	+32%	+$4.45M	0.36%	91
2014 Q3	$12.6M	Buy	500,000 +135,454	+37%	+$3.57M	0.26%	121
2014 Q2	$10.6M	Buy	+364,546	New	+$8.82M	0.23%	146

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Polar Capital's PTLA Position: Q4 2019 in Review

Polar Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 471,362 shares — an estimated $12.6M sold.

Polar Capital first reported a position in PTLA in Q2 2014 and held it in 11 quarters. The position peaked at $31.8M in Q3 2017. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

Polar Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Polar Capital sold 471,362 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $12.6M.
Polar Capital first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 11 quarters.
Polar Capital's Portola Pharmaceuticals, Inc. position peaked at $31.8M in Q3 2017.
224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on Polar Capital's 13F filing for Q4 2019, filed 14 Feb 2020.